

MESA LABORATORIES INC /CO  
Form SC 13D/A  
September 15, 2005

=====

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

SCHEDULE 13D  
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO  
RULE 13d-2(a)  
(Amendment No. 2) (1)

Mesa Laboratories, Inc.

-----  
(Name of Issuer)

Common Stock, no par value

-----  
(Title of Class of Securities)

59064R 10 9

-----  
(CUSIP Number)

Farnam Street Partners, L.P.  
Farnam Street Capital, Inc.  
3033 Excelsior Boulevard, Suite 300  
Minneapolis, MN 55416  
Phone: (612) 253-6058

With a copy to:  
Douglas T. Holod, Esq.  
Maslon Edelman Borman & Brand, LLP  
3300 Wells Fargo Center  
90 South Seventh Street  
Minneapolis, MN 55402-4140  
Phone: (612) 672-8200

-----  
(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

September 13, 2005

-----  
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box / /.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D/A

240.13d-7 for other parties to whom copies are to be sent.

(1) The remainder of this cover page shall be filled out for a

reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

=====

CUSIP No. 59064R 10 9

Page 2 of 8

1 NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Farnam Street Partners, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

- (a) [ ]
(b) [ ]

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

OO (Investment proceeds)

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ]

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Minnesota

7 SOLE VOTING POWER
NUMBER OF SHARES 146,884

8 SHARED VOTING POWER
BENEFICIALLY OWNED BY EACH REPORTING 0

9 SOLE DISPOSITIVE POWER

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D/A

146,884  
PERSON -----  
10 SHARED DISPOSITIVE POWER  
WITH  
0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

146,884

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) [ ]

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

4.8%

14 TYPE OF REPORTING PERSON (See Instructions)

PN

CUSIP No. 59064R 10 9

Page 3 of 8

1 NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Farnam Street Capital, Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

(a) [ ]

(b) [ ]

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

OO (Investment proceeds)

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

[ ]

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Minnesota

7 SOLE VOTING POWER  
NUMBER OF  
146,884 (See Explanation in Item 5)  
SHARES  
8 SHARED VOTING POWER

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D/A

BENEFICIALLY  
0  
OWNED BY EACH -----  
9 SOLE DISPOSITIVE POWER  
REPORTING  
146,884 (See Explanation in Item 5)  
PERSON -----  
10 SHARED DISPOSITIVE POWER  
WITH  
0

-----  
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
146,884

-----  
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES  
CERTAIN SHARES (See Instructions) [ ]

-----  
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
4.8%

-----  
14 TYPE OF REPORTING PERSON (See Instructions)  
PN  
-----

CUSIP No. 59064R 10 9 Page 4 of 8

-----  
1 NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS  
(ENTITIES ONLY)  
Raymond E. Cabillot

-----  
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(See Instructions)  
(a) [ ]  
(b) [ ]

-----  
3 SEC USE ONLY

-----  
4 SOURCE OF FUNDS (See Instructions)  
None

-----  
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT  
TO ITEMS 2(d) OR 2(e)  
[ ]

-----  
6 CITIZENSHIP OR PLACE OF ORGANIZATION  
Minnesota  
-----

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D/A

NUMBER OF	7	SOLE VOTING POWER	
SHARES	0		
-----			
BENEFICIALLY	8	SHARED VOTING POWER	
OWNED BY EACH	146,884		
-----			
REPORTING	9	SOLE DISPOSITIVE POWER	
PERSON	0		
-----			
WITH	10	SHARED DISPOSITIVE POWER	
	146,884		
-----			
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	0 (See Item 5(b))		
-----			
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)		[X]
	See explanation in Item 5		
-----			
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)		
	0%		
-----			
14	TYPE OF REPORTING PERSON (See Instructions)		
	IN		
-----			

CUSIP No. 59064R 10 9

Page 5 of 8

1	NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)		
	Peter O. Haeg		
-----			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)		
	(a) [ ]		
	(b) [ ]		
-----			
3	SEC USE ONLY		
-----			
4	SOURCE OF FUNDS (See Instructions)		
	None		
-----			

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D/A

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)  
[ ]

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Minnesota

NUMBER OF	7	SOLE VOTING POWER
SHARES	0	
BENEFICIALLY	8	SHARED VOTING POWER
OWNED BY EACH	146,884	
REPORTING	9	SOLE DISPOSITIVE POWER
PERSON	0	
WITH	10	SHARED DISPOSITIVE POWER
	146,884	

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

0 (See Item 5(b))

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) [X]

See explanation in Item 5

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

0%

14 TYPE OF REPORTING PERSON (See Instructions)

IN

ITEM 1. SECURITY AND ISSUER

This statement relates to the common stock, no par value, of Mesa Laboratories, Inc., a Colorado corporation ("Mesa" or the "Company" or the "Issuer"). The address of the Company's principal executive offices is 12100 West Sixth Avenue, Lakewood, CO 80228.

ITEM 2. IDENTITY AND BACKGROUND

(a) This Amendment to Schedule 13D is being filed by Farnam Street Partners, L.P., a Minnesota Limited Partnership (the "Fund"), and by its General Partner, Farnam Street Capital, Inc., a Minnesota corporation ("FSC"). Mr.

## Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D/A

Raymond E. Cabillot is Chief Executive Officer and Chief Financial Officer and Mr. Peter O. Haeg is President and Secretary of FSC. The Fund and FSC are making this filing because they are no longer the beneficial owner, pursuant to Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"), of more than five percent (5%) of the outstanding shares of Common Stock of the Issuer.

(b) The principal office of the Fund, FSC and Messrs. Cabillot and Haeg is 3033 Excelsior Boulevard, Suite 300, Minneapolis, Minnesota 55416.

(c) The Fund was organized in January 1998 as a Minnesota Limited Partnership. FSC is a Minnesota corporation. Its principal business activities involve investing in equity securities of publicly traded companies, as well as other types of securities.

(d) - (e) During the last five years, neither the Fund, FSC nor the principals of its General Partner have been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) nor have the parties been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such individual was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting, or mandating activity subject to, federal or state securities laws or finding any violation with respect to such laws.

### ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

The aggregate sales price of the purchases identified in response to Item 5(c) was \$1,095,997.36. All securities identified in response to Item 5(c) were sold in open market purchases.

### ITEM 4. PURPOSE OF TRANSACTION

All of the shares of the Company owned by the Reporting Person were, at the time of their purchase, acquired for investment purposes in the ordinary course of business. FSC makes investments in companies that it believes are undervalued and represent an attractive investment opportunity. FSC may from time to time purchase additional shares of the Company's stock or dispose of all or some of the shares.

FSC has no present plans or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. FSC intends to review its investment in the Issuer on a continuing basis and, depending on various factors, including, without limitation, the Issuer's financial position and investment strategy, the price levels of the common stock, conditions in the securities markets, conditions in the industry and general economic conditions, may in the future take such actions with respect to its investment in the Issuer as it deems appropriate including, without limitation, purchasing additional shares of common stock or selling some or all of its shares or to change its intention with respect to any and all matters to in Item 4.

### ITEM 5. INTEREST IN THE SECURITIES OF THE ISSUER

(a) FSC manages the Fund which beneficially owns 146,884 shares of common stock of the Issuer, representing 4.8% of the shares outstanding (based

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D/A

upon 3,034,595 shares outstanding on June 30, 2005, as reported in the Issuer's most recent 10-Q filed on August 12, 2005).

(b) The Fund does not share voting and dispositive power with respect to any shares. However, Messrs. Cabillot and Haeg, as officers of FSC, may be deemed to have beneficial ownership of the shares reported in this Schedule 13D/A by virtue of their shared voting and dispositive power. However, they disclaim beneficial ownership and have no direct pecuniary interest in the shares.

(c) TRANSACTIONS WITHIN THE LAST 60 DAYS OR SINCE THE LAST FILING.

The following sales took place within the last 60 days:

No. of Trade Date	Price per Shares	share
9/12/2005	31	\$12.50
9/13/2005	89,439	\$12.2498

(d) Not applicable.

(e) On September 13, 2005, the Reporting Person ceased to be a beneficial owner of more than 5% of the class of securities.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS WITH RESPECT TO SECURITIES OF THE ISSUER

There are no contracts, arrangements, understandings or relationships between the Fund or FSC, on one hand, and any other person with respect to any securities of the Issuer on the other hand.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

None

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

Dated: September 15, 2005

FARNAM STREET PARTNERS, L.P.  
BY: FARNAM STREET CAPITAL, INC.,  
General Partner

By: /s/ Raymond E. Cabillot

Raymond E. Cabillot,



Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D/A

Chief Executive Officer

By: /s/ Peter O. Haeg

-----  
Peter O. Haeg,  
President

/s/ Raymond E. Cabillot

-----  
RAYMOND E. CABILLOT

/s/ Peter O. Haeg

-----  
PETER O. HAEG